Man Group PLC Affimed N.V. Transaction History

Man Group PLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.66 - $1.29 $69,088 - $135,037	-104,680 Reduced 63.98%	58,928 $44,000
Q4 2022 Feb 14, 2023	BUY	$1.1 - $2.45 $124,748 - $277,849	113,408 Added 225.91%	163,608 $202,000
Q3 2022 Nov 14, 2022	BUY	$1.96 - $3.32 $21,168 - $35,856	10,800 Added 27.41%	50,200 $103,000
Q2 2022 Aug 15, 2022	BUY	$2.27 - $4.86 $89,438 - $191,484	39,400 New	39,400 $109,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.